Search Results 1091-1100 of 18545 for hepatitis

  1. MEDI5752 In Combination With Carboplatin Plus Pemetrexed In Unresectable Pleural Mesothelioma - Mayo Clinic

    * History of another primary malignancy with exceptions. * Uncontrolled intercurrent illness * Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human ...

  2. A Study to Evaluate the Safety and Effectiveness of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa Evaluating the Safety and Effectiveness of PF-06650833, PF-06700841, and PF-06826647 in Adults with Moderate-to-Severe Hidradenitis Suppurativa - Mayo Clinic

    Infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses: Participants who are hepatitis C virus (HCV) antibody (Ab) positive ...

  3. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) - Mayo Clinic

    * Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable ...

  4. Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) - Mayo Clinic

    Positive for Hepatitis B, Hepatitis C, or Human Deficiency Virus; Severe Renal Impairment; Contraindications for MRI. Participating Mayo Clinic locations. Study ...

  5. AKT Inhibitor MK2206, Combined with Bendamustine Hydrochloride, and Rituximab for Treating Patients who have Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

    Infection with known chronic, active hepatitis C; Positive serology for hepatitis B (HB) defined as a positive test for hepatitis B surface antigen (HBsAg).

  6. A Study Of The Pan-KRAS Inhibitor LY4066434 In Participants With KRAS Mutant Solid Tumors - Mayo Clinic

    * Have known active hepatitis B virus (HBV), hepatitis C virus (HCV) and untreated HIV infection * Have other active malignancy unless in remission with ...

  7. Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma - Mayo Clinic

    Has known history of chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (detectable anti-hepatitis C ...

  8. Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation - Mayo Clinic

    Is nursing or pregnant · DLBCL of GCB subtype · Has BMI > 34.9 kg/m2 · Has a positive test for human immunodeficiency virus (HIV-1 or -2) hepatitis C virus (HCV) ...

  9. Drugs and Supplements that Start with E - Mayo Clinic

    Hepatitis b vaccine (intramuscular route). Engerix-B Pediatric. Also known as. Hepatitis b vaccine (intramuscular route). Enhertu. Also known as. Fam- ...

  10. A Study of Axatilimab at 3 Different Doses in Patients With Chronic Graft Versus Host Disease (cGVHD) - Mayo Clinic

    Hepatitis C (defined as positive hepatitis C [HCV] antibody with positive HCV ribonucleic acid [RNA]). 8. Diagnosed with another malignancy (other than ...